Cargando…

Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms

Tumor marker determinations are valuable tools for the guidance of breast cancer patients during the course of disease. They are assessed on diverse analytical platforms that may be associated with differences according to the methods applied and the clinical performance. To investigate the method d...

Descripción completa

Detalles Bibliográficos
Autores principales: Schröder, Lars, Mallmann, Michael R., Domroese, Christian M., Wefers, Natalie, Dolscheid-Pommerich, Ramona, Stoffel-Wagner, Birgit, Trulson, Inga, Vahldiek, Kai, Klawonn, Frank, Holdenrieder, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572608/
https://www.ncbi.nlm.nih.gov/pubmed/37835844
http://dx.doi.org/10.3390/diagnostics13193101
_version_ 1785120273015504896
author Schröder, Lars
Mallmann, Michael R.
Domroese, Christian M.
Wefers, Natalie
Dolscheid-Pommerich, Ramona
Stoffel-Wagner, Birgit
Trulson, Inga
Vahldiek, Kai
Klawonn, Frank
Holdenrieder, Stefan
author_facet Schröder, Lars
Mallmann, Michael R.
Domroese, Christian M.
Wefers, Natalie
Dolscheid-Pommerich, Ramona
Stoffel-Wagner, Birgit
Trulson, Inga
Vahldiek, Kai
Klawonn, Frank
Holdenrieder, Stefan
author_sort Schröder, Lars
collection PubMed
description Tumor marker determinations are valuable tools for the guidance of breast cancer patients during the course of disease. They are assessed on diverse analytical platforms that may be associated with differences according to the methods applied and the clinical performance. To investigate the method dependency and clinical significance of breast cancer protein tumor markers, CEA, CA 15-3, CA 125, CA 19-9 and AFP were measured in a total of 154 biobanked samples from 77 patients with breast cancer, 10 with DCIS, 31 with benign breast diseases and 36 healthy controls using a Millipore multiplex biomarker panel (MP) and an automized version of the routinely used Vista LOCI technology. The markers were compared between methods and investigated for diagnostic performance. CEA, CA 15-3 and AFP showed good correlations between both platforms with correlation coefficients of R = 0.85, 0.85 and 0.92, respectively, in all samples, but similarly also in the various subgroups. CA 125 and CA 19-9 showed only moderate correlations (R = 0.71 and 0.56, respectively). Absolute values were significantly higher for CEA, CA 15-3, CA 125 and AFP in the Vista LOCI as compared with the MP method and vice versa for CA 19-9. The diagnostic performance for discrimination of breast cancer from healthy controls was similar for both methods with AUCs in ROC curves for CEA (MP 0.81, 95% CI 0.72–0.91; LOCI 0.81; 95% CI 0.72–0.91) and CA-15-3 (MP 0.75, 95% CI 0.65–0.86; LOCI 0.67, 95% CI 0.54–0.79). Similar results were obtained for the comparison of breast cancer with benign breast diseases regarding CEA (AUC MP 0.62, 95% CI 0.51–0.73; LOCI 0.64, 95% CI 0.53–0.74) and CA-15-3 (MP 0.70, 95% CI 0.6–0.81; LOCI 0.66, 95% CI 0.54–0.77). Both platforms show moderate to good method comparability for tumor markers with similar clinical performance. However, absolute levels in individual patients should be interpreted with care.
format Online
Article
Text
id pubmed-10572608
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105726082023-10-14 Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms Schröder, Lars Mallmann, Michael R. Domroese, Christian M. Wefers, Natalie Dolscheid-Pommerich, Ramona Stoffel-Wagner, Birgit Trulson, Inga Vahldiek, Kai Klawonn, Frank Holdenrieder, Stefan Diagnostics (Basel) Article Tumor marker determinations are valuable tools for the guidance of breast cancer patients during the course of disease. They are assessed on diverse analytical platforms that may be associated with differences according to the methods applied and the clinical performance. To investigate the method dependency and clinical significance of breast cancer protein tumor markers, CEA, CA 15-3, CA 125, CA 19-9 and AFP were measured in a total of 154 biobanked samples from 77 patients with breast cancer, 10 with DCIS, 31 with benign breast diseases and 36 healthy controls using a Millipore multiplex biomarker panel (MP) and an automized version of the routinely used Vista LOCI technology. The markers were compared between methods and investigated for diagnostic performance. CEA, CA 15-3 and AFP showed good correlations between both platforms with correlation coefficients of R = 0.85, 0.85 and 0.92, respectively, in all samples, but similarly also in the various subgroups. CA 125 and CA 19-9 showed only moderate correlations (R = 0.71 and 0.56, respectively). Absolute values were significantly higher for CEA, CA 15-3, CA 125 and AFP in the Vista LOCI as compared with the MP method and vice versa for CA 19-9. The diagnostic performance for discrimination of breast cancer from healthy controls was similar for both methods with AUCs in ROC curves for CEA (MP 0.81, 95% CI 0.72–0.91; LOCI 0.81; 95% CI 0.72–0.91) and CA-15-3 (MP 0.75, 95% CI 0.65–0.86; LOCI 0.67, 95% CI 0.54–0.79). Similar results were obtained for the comparison of breast cancer with benign breast diseases regarding CEA (AUC MP 0.62, 95% CI 0.51–0.73; LOCI 0.64, 95% CI 0.53–0.74) and CA-15-3 (MP 0.70, 95% CI 0.6–0.81; LOCI 0.66, 95% CI 0.54–0.77). Both platforms show moderate to good method comparability for tumor markers with similar clinical performance. However, absolute levels in individual patients should be interpreted with care. MDPI 2023-09-30 /pmc/articles/PMC10572608/ /pubmed/37835844 http://dx.doi.org/10.3390/diagnostics13193101 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schröder, Lars
Mallmann, Michael R.
Domroese, Christian M.
Wefers, Natalie
Dolscheid-Pommerich, Ramona
Stoffel-Wagner, Birgit
Trulson, Inga
Vahldiek, Kai
Klawonn, Frank
Holdenrieder, Stefan
Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms
title Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms
title_full Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms
title_fullStr Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms
title_full_unstemmed Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms
title_short Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms
title_sort method comparison and clinical performance of breast cancer tumor markers on novel multiplex immunoassay and automatized loci technology platforms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572608/
https://www.ncbi.nlm.nih.gov/pubmed/37835844
http://dx.doi.org/10.3390/diagnostics13193101
work_keys_str_mv AT schroderlars methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms
AT mallmannmichaelr methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms
AT domroesechristianm methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms
AT wefersnatalie methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms
AT dolscheidpommerichramona methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms
AT stoffelwagnerbirgit methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms
AT trulsoninga methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms
AT vahldiekkai methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms
AT klawonnfrank methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms
AT holdenriederstefan methodcomparisonandclinicalperformanceofbreastcancertumormarkersonnovelmultipleximmunoassayandautomatizedlocitechnologyplatforms